PT2206719E - Composição farmacêutica compreendendo 3-beta-hidroxi-17- (1-h-benzimidazol-1-il)androsta-5,16-dieno - Google Patents
Composição farmacêutica compreendendo 3-beta-hidroxi-17- (1-h-benzimidazol-1-il)androsta-5,16-dieno Download PDFInfo
- Publication number
- PT2206719E PT2206719E PT101507630T PT10150763T PT2206719E PT 2206719 E PT2206719 E PT 2206719E PT 101507630 T PT101507630 T PT 101507630T PT 10150763 T PT10150763 T PT 10150763T PT 2206719 E PT2206719 E PT 2206719E
- Authority
- PT
- Portugal
- Prior art keywords
- diene
- methods
- androsta
- benzimidazole
- beta
- Prior art date
Links
- PAFKTGFSEFKSQG-PAASFTFBSA-N Galeterone Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CC=C3[C@@]4(CC[C@H](O)C3)C)[C@@H]4CC[C@@]21C PAFKTGFSEFKSQG-PAASFTFBSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical class N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 abstract 2
- 102000001307 androgen receptors Human genes 0.000 abstract 2
- 108010080146 androgen receptors Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 101100298362 Homo sapiens PPIG gene Proteins 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000004891 diazines Chemical class 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 102000056262 human PPIG Human genes 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000012038 nucleophile Substances 0.000 abstract 1
- 230000000269 nucleophilic effect Effects 0.000 abstract 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- DBHSVKZZSWTSTN-UHFFFAOYSA-N tributyl(pyridazin-3-yl)stannane Chemical class CCCC[Sn](CCCC)(CCCC)C1=CC=CN=N1 DBHSVKZZSWTSTN-UHFFFAOYSA-N 0.000 abstract 1
- 125000002348 vinylic group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65739005P | 2005-03-02 | 2005-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2206719E true PT2206719E (pt) | 2015-02-05 |
Family
ID=36941503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT101507630T PT2206719E (pt) | 2005-03-02 | 2006-03-02 | Composição farmacêutica compreendendo 3-beta-hidroxi-17- (1-h-benzimidazol-1-il)androsta-5,16-dieno |
| PT06736460T PT1853619E (pt) | 2005-03-02 | 2006-03-02 | 3-beta-hidroxi-17-(1h-benzimidazol-1-il)androsta-5,16-dieno para utilização no tratamento de uma doença da próstata |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT06736460T PT1853619E (pt) | 2005-03-02 | 2006-03-02 | 3-beta-hidroxi-17-(1h-benzimidazol-1-il)androsta-5,16-dieno para utilização no tratamento de uma doença da próstata |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7875599B2 (enExample) |
| EP (2) | EP1853619B1 (enExample) |
| JP (2) | JP5130453B2 (enExample) |
| KR (1) | KR101380959B1 (enExample) |
| CN (2) | CN101155823A (enExample) |
| AT (1) | ATE482969T1 (enExample) |
| AU (1) | AU2006218711B2 (enExample) |
| BR (1) | BRPI0607523A2 (enExample) |
| CA (1) | CA2599953C (enExample) |
| DE (1) | DE602006017175D1 (enExample) |
| DK (2) | DK2206719T3 (enExample) |
| EA (1) | EA019560B1 (enExample) |
| ES (2) | ES2528055T3 (enExample) |
| IL (3) | IL185608A (enExample) |
| MX (1) | MX2007010593A (enExample) |
| NZ (1) | NZ561571A (enExample) |
| PL (2) | PL1853619T3 (enExample) |
| PT (2) | PT2206719E (enExample) |
| SI (2) | SI1853619T1 (enExample) |
| WO (1) | WO2006093993A1 (enExample) |
| ZA (1) | ZA200708106B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
| EA019560B1 (ru) * | 2005-03-02 | 2014-04-30 | Юнивесити Оф Мэриленд, Балтимор | Способ лечения простаты (варианты) |
| US20100047338A1 (en) * | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| WO2008154402A2 (en) | 2007-06-06 | 2008-12-18 | University Of Maryland, Baltimore | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| GB2470873A (en) * | 2008-03-12 | 2010-12-08 | Univ Maryland | Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer |
| US20110118219A1 (en) * | 2008-03-25 | 2011-05-19 | University Of Maryland, Baltimore | Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity |
| US8785423B2 (en) * | 2008-04-14 | 2014-07-22 | University Of Maryland, Baltimore | Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases |
| WO2010024930A2 (en) | 2008-08-28 | 2010-03-04 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses therof |
| US20100105700A1 (en) * | 2008-10-28 | 2010-04-29 | Lead Therapeutics, Inc. | Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors |
| GB2514957A (en) * | 2009-02-05 | 2014-12-10 | Tokai Pharmaceuticals Inc | Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent |
| US8791095B2 (en) | 2009-02-05 | 2014-07-29 | Tokai Pharmaceuticals, Inc. | Steroidal CYP17 inhibitors/antiandrogens |
| AU2010210422A1 (en) * | 2009-02-05 | 2011-08-18 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens |
| UY32730A (es) | 2009-06-26 | 2011-01-31 | Novartis Ag | Inhibidores de cyp17 |
| AU2010279398A1 (en) * | 2009-08-07 | 2012-03-08 | Tokai Pharmaceuticals, Inc. | Treatment of prostate cancer |
| EP2499151A4 (en) * | 2009-11-13 | 2013-03-20 | Tokai Pharmaceuticals Inc | MAMMALIAN STEROID METABOLITES |
| CA2782266A1 (en) * | 2009-11-30 | 2011-06-03 | Harbor Biosciences, Inc. | Anticancer compounds and screening method |
| EP2627648A1 (en) | 2010-09-16 | 2013-08-21 | Novartis AG | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS |
| WO2012083112A2 (en) * | 2010-12-16 | 2012-06-21 | Biomarin Pharmaceutical Inc. | Cyp11b, cyp17, and/or cyp21 inhibitors |
| MX359399B (es) | 2011-04-28 | 2018-09-27 | Novartis Ag | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. |
| JP2014523445A (ja) * | 2011-07-18 | 2014-09-11 | トーカイ ファーマシューティカルズ，インク． | 前立腺癌を処置するための新規な組成物及び方法 |
| US20150005265A1 (en) * | 2011-12-22 | 2015-01-01 | Susan Stewart | Methods and compositions for combination therapy using p13k/mtor inhibitores |
| KR20150127720A (ko) | 2013-03-14 | 2015-11-17 | 유니버시티 오브 매릴랜드, 발티모어 | 안드로겐 수용체 하향 조절제 및 그의 용도 |
| EP2991644B1 (en) | 2013-04-04 | 2020-03-25 | University of Maryland, Baltimore | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity |
| WO2015023710A1 (en) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| ES2709480T3 (es) | 2013-12-24 | 2019-04-16 | Harvard College | Análogos de cortistatina y síntesis y usos de los mismos |
| CN103694299A (zh) * | 2014-01-13 | 2014-04-02 | 中国药科大学 | 甾体类雄激素受体抑制剂、其制备方法及其医药用途 |
| CN105732759A (zh) * | 2015-01-29 | 2016-07-06 | 苏州晶云药物科技有限公司 | (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法 |
| EP3294298A4 (en) | 2015-05-08 | 2018-10-17 | President and Fellows of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
| WO2017004411A1 (en) | 2015-07-01 | 2017-01-05 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| WO2017066697A1 (en) | 2015-10-14 | 2017-04-20 | Dou Qingping | Treatments and diagnostics for cancers |
| IT201600083406A1 (it) * | 2016-08-08 | 2018-02-08 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE |
| WO2018029223A1 (en) * | 2016-08-08 | 2018-02-15 | Industriale Chimica S.R.L. | PROCESS FOR THE PREPARATION OF 3ß-HYDROXY-17-(1H-BENZIMIDAZOL-1-YL)ANDROSTA-5,16-DIENE |
| IT201600121375A1 (it) * | 2016-11-30 | 2018-05-30 | Ind Chimica Srl | PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE |
| ES3026226T3 (en) * | 2018-02-13 | 2025-06-10 | Dana Farber Cancer Inst Inc | Cyclin-dependent kinase degraders and methods of use |
| CA3089588A1 (en) * | 2018-02-13 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Cyclin-dependent kinase inhibitors and methods of use |
| US12410194B2 (en) | 2019-11-26 | 2025-09-09 | Dana-Farber Cancer Institute, Inc. | Potent and selective azaindole inhibitors of CDK8 and CDK19 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA27440A (en) | 1887-08-16 | James T. Walsh | Art of making sheet metal cans, for packing meats, fruits, vegetables, etc. | |
| CH621803A5 (enExample) * | 1974-08-08 | 1981-02-27 | Siphar Sa | |
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| US5994335A (en) | 1997-10-17 | 1999-11-30 | The University Of Maryland, Baltimore | 17-azolyl steroids useful as androgen synthesis inhibitors |
| PL1660115T3 (pl) | 2003-07-29 | 2011-11-30 | Dompe Spa | Farmaceutyczna kombinacja G-CSF i PLGF użyteczna wobec komórek macierzystych krwi |
| EA019560B1 (ru) * | 2005-03-02 | 2014-04-30 | Юнивесити Оф Мэриленд, Балтимор | Способ лечения простаты (варианты) |
-
2006
- 2006-03-02 EA EA200701872A patent/EA019560B1/ru not_active IP Right Cessation
- 2006-03-02 PL PL06736460T patent/PL1853619T3/pl unknown
- 2006-03-02 PT PT101507630T patent/PT2206719E/pt unknown
- 2006-03-02 MX MX2007010593A patent/MX2007010593A/es active IP Right Grant
- 2006-03-02 PT PT06736460T patent/PT1853619E/pt unknown
- 2006-03-02 BR BRPI0607523-1A patent/BRPI0607523A2/pt not_active IP Right Cessation
- 2006-03-02 AU AU2006218711A patent/AU2006218711B2/en not_active Expired
- 2006-03-02 US US11/817,550 patent/US7875599B2/en active Active
- 2006-03-02 CN CNA2006800064632A patent/CN101155823A/zh active Pending
- 2006-03-02 KR KR1020077022440A patent/KR101380959B1/ko not_active Expired - Fee Related
- 2006-03-02 JP JP2007558143A patent/JP5130453B2/ja not_active Expired - Lifetime
- 2006-03-02 EP EP06736460A patent/EP1853619B1/en not_active Expired - Lifetime
- 2006-03-02 EP EP10150763.0A patent/EP2206719B1/en not_active Expired - Lifetime
- 2006-03-02 CA CA2599953A patent/CA2599953C/en not_active Expired - Lifetime
- 2006-03-02 DK DK10150763.0T patent/DK2206719T3/en active
- 2006-03-02 PL PL10150763T patent/PL2206719T3/pl unknown
- 2006-03-02 SI SI200630861T patent/SI1853619T1/sl unknown
- 2006-03-02 NZ NZ561571A patent/NZ561571A/en not_active IP Right Cessation
- 2006-03-02 SI SI200631883T patent/SI2206719T1/sl unknown
- 2006-03-02 DK DK06736460.4T patent/DK1853619T3/da active
- 2006-03-02 AT AT06736460T patent/ATE482969T1/de active
- 2006-03-02 CN CN2013101036754A patent/CN103349664A/zh active Pending
- 2006-03-02 WO PCT/US2006/007143 patent/WO2006093993A1/en not_active Ceased
- 2006-03-02 ES ES10150763.0T patent/ES2528055T3/es not_active Expired - Lifetime
- 2006-03-02 DE DE602006017175T patent/DE602006017175D1/de not_active Expired - Lifetime
- 2006-03-02 ES ES06736460T patent/ES2353413T3/es not_active Expired - Lifetime
-
2007
- 2007-08-30 IL IL185608A patent/IL185608A/en not_active IP Right Cessation
- 2007-09-20 ZA ZA200708106A patent/ZA200708106B/xx unknown
-
2011
- 2011-01-06 IL IL210480A patent/IL210480A/en not_active IP Right Cessation
- 2011-01-06 IL IL210478A patent/IL210478A0/en unknown
-
2012
- 2012-09-06 JP JP2012196525A patent/JP5613206B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2206719T3 (pl) | Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien | |
| PT1353672E (pt) | Síntese da 4-amino talidomida enantiómeros | |
| EP2966065A3 (en) | Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors | |
| WO2007087548A3 (en) | Chemical compounds | |
| PT1934174E (pt) | Azetidinas como inibidores de mek para o tratamento de doenças proliferativas | |
| MX2009003876A (es) | Uso de compuestos de espiro-oxindol como agentes terapeuticos. | |
| WO2009120565A3 (en) | Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity | |
| NO20076319L (no) | Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav | |
| AU2010210422A8 (en) | Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens | |
| GEP20115213B (en) | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | |
| MXPA06009475A (es) | Derivados de quinazolina y usos terapeuticos de los mismos. | |
| TW200833698A (en) | Spiroheterocyclic compounds and their uses as therapeutic agents | |
| WO2005077968A3 (en) | 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity | |
| WO2005103010A3 (en) | Pyrazole derivatives useful for the treatment of cancer | |
| WO2008011539A3 (en) | Anesthetic compounds | |
| CY1115910T1 (el) | ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE | |
| WO2007045060A8 (en) | Pharmaceutical compositions containing erythrine mulungu derivatives and processes for their production | |
| UA93198C2 (ru) | Производные пиразола, способ их получения, их применения, фармацевтическая композиция (варианты) и способ лечения злокачественного новообразования (варианты) | |
| TW200603812A (en) | D-homo-17-chlor-16(17)-ene steroids | |
| TW200504044A (en) | Methods for preparing derivatives of fungicidal iodochromones and intermediate compounds | |
| UA96742C2 (en) | Mek inhibitors and use thereof |